iSpecimen Amends S-1/A, Adds Solana Treasury Plan & Nasdaq Noncompliance

TL;DR

**ISPC's S-1/A reveals a risky pivot to Solana blockchain and ongoing Nasdaq listing woes, making it a speculative play for traders.**

AI Summary

iSpecimen Inc. (ISPC) filed an S-1/A on September 8, 2025, to register 1,559,828 shares of common stock for resale by selling stockholders, comprising 267,379 shares and 1,292,449 warrant shares from an August 2025 private placement. The company will not receive proceeds from these sales, but may receive up to $0.0001 per share upon warrant exercise. A significant update includes new disclosures regarding iSpecimen's corporate treasury plan involving the Solana blockchain ecosystem and related risk factors. The filing also addresses a June 4, 2025, Nasdaq noncompliance letter concerning Listing Rule 5550(b)(1). iSpecimen, an 'emerging growth company,' operates a global marketplace connecting researchers to biospecimens and data, aiming to enhance customer experience, increase supplier engagement, and improve operational efficiency. The last reported sale price for ISPC common stock was $0.8536 per share on September 5, 2025.

Why It Matters

This S-1/A filing is crucial for investors as it details the resale of over 1.5 million shares by selling stockholders, potentially increasing market float and impacting share price, especially given the current $0.8536 per share price. The introduction of a corporate treasury plan involving the Solana blockchain ecosystem signals a new strategic direction, but also introduces novel, potentially high-risk exposure for investors. Furthermore, the ongoing Nasdaq noncompliance issue (Rule 5550(b)(1)) raises concerns about the company's listing status, which could severely affect liquidity and investor confidence. Competitively, this blockchain move could differentiate iSpecimen in the biospecimen market, but also divert resources from its core marketplace platform development.

Risk Assessment

Risk Level: high — The risk level is high due to the introduction of a corporate treasury plan relating to the Solana blockchain ecosystem, which inherently carries significant volatility and regulatory uncertainty. Additionally, the company is in noncompliance with Nasdaq Listing Rule 5550(b)(1) as of June 4, 2025, indicating a potential delisting risk that could severely impact stock liquidity and investor confidence.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate the new risk factors associated with iSpecimen's Solana blockchain treasury plan. Given the Nasdaq noncompliance, consider the potential for delisting and its impact on liquidity before making any investment decisions. This filing suggests a highly speculative investment.

Key Numbers

• 1,559,828 — Shares of Common Stock (Total shares offered for resale by selling stockholders)
• 267,379 — Shares of Common Stock (Direct shares held by selling stockholders from August 2025 Private Placement)
• 1,292,449 — Warrant Shares (Shares issuable upon exercise of pre-funded warrants from August 2025 Private Placement)
• $0.0001 — Nominal Exercise Price per Warrant Share (Price at which warrants can be exercised)
• $0.8536 — Last Reported Sale Price per Share (ISPC common stock price on September 5, 2025)
• September 13, 2024 — Reverse Stock Split Date (Date of 1-for-20 reverse stock split)
• June 4, 2025 — Nasdaq Noncompliance Letter Date (Date iSpecimen received notice of noncompliance with Nasdaq Listing Rule 5550(b)(1))
• August 20, 2025 — Original S-1 Filing Date (Date iSpecimen Inc. originally filed its S-1 Registration Statement)
• August 29, 2025 — SEC Comment Letter Date (Date of SEC Staff's letter prompting S-1/A amendments)
• April 14, 2025 — Audit Report Date (Date of Bush & Associates CPA LLC's audit report)

Key Players & Entities

• iSpecimen Inc. (company) — Registrant
• Katharyn Field (person) — President of iSpecimen Inc.
• Securities and Exchange Commission (regulator) — Regulatory body for S-1/A filing
• The Nasdaq Stock Market LLC (company) — Stock exchange where ISPC is listed
• Solana (company) — Blockchain ecosystem for corporate treasury plan
• Bush & Associates CPA LLC (company) — Auditor referenced in Exhibit 23.2
• Ross D. Carmel, Esq. (person) — Counsel from Sichenzia Ross Ference Carmel LLP
• Barry P. Biggar, Esq. (person) — Counsel from Sichenzia Ross Ference Carmel LLP
• Benjamin E. Sklar, Esq. (person) — Counsel from Sichenzia Ross Ference Carmel LLP
• Sichenzia Ross Ference Carmel LLP (company) — Legal counsel for iSpecimen Inc.

FAQ

Risk Factors

• Nasdaq Noncompliance [high — regulatory]: The company received a Nasdaq noncompliance letter on June 4, 2025, for failing to meet Listing Rule 5550(b)(1). This rule typically relates to minimum bid price or market capitalization requirements. Failure to regain compliance could lead to delisting from Nasdaq.
• Reliance on Private Placements [medium — financial]: The current S-1/A filing is to register shares from an August 2025 private placement. This indicates a reliance on private capital raises, which may not be sustainable and could dilute existing shareholders. The company will not receive proceeds from the resale of these shares.
• Blockchain Ecosystem Integration Risks [medium — operational]: The company's new corporate treasury plan involves the Solana blockchain ecosystem. This introduces risks related to the volatility and security of cryptocurrency, regulatory uncertainty surrounding digital assets, and the technical complexities of integrating blockchain technology.
• Limited Proceeds from Resale [low — financial]: The S-1/A filing registers 1,559,828 shares for resale by selling stockholders. The company itself will not receive any proceeds from these sales, except for a nominal $0.0001 per share upon warrant exercise, limiting its ability to fund operations through this mechanism.
• Dependence on Third-Party Suppliers [medium — operational]: As a marketplace connecting researchers to biospecimens, iSpecimen relies heavily on its network of suppliers. Disruptions in the supply chain, quality control issues with biospecimens, or a decline in supplier engagement could negatively impact the company's ability to fulfill orders.

Industry Context

iSpecimen operates in the biospecimen and research data market, a niche but critical segment supporting pharmaceutical, biotechnology, and academic research. The industry is characterized by increasing demand for high-quality, well-characterized biological samples for drug discovery, diagnostics, and personalized medicine. Key trends include the digitization of research data, the need for efficient sample sourcing and logistics, and growing regulatory scrutiny over sample provenance and ethical sourcing.

Regulatory Implications

The company faces significant regulatory risks, including potential delisting from Nasdaq due to noncompliance with Listing Rule 5550(b)(1). Furthermore, its new corporate treasury plan involving the Solana blockchain introduces potential regulatory uncertainties related to digital assets and cryptocurrency. Compliance with SEC reporting requirements remains paramount, especially given the ongoing registration of shares for resale.

What Investors Should Do

1. Monitor Nasdaq compliance status closely: The June 4, 2025, noncompliance letter presents a material risk of delisting. Investors should track any further communications from Nasdaq and the company's progress in regaining compliance.
2. Evaluate the blockchain treasury plan risks: The integration of the Solana ecosystem introduces volatility and regulatory uncertainty. Investors should assess their risk tolerance for exposure to digital assets and the associated technological and security risks.
3. Analyze the dilution impact of private placements: The current filing highlights reliance on private capital. Investors should consider the potential for future dilution and the company's ability to generate sustainable revenue growth to offset it.
4. Assess the operational risks of the marketplace model: The company's reliance on third-party suppliers for biospecimens creates operational vulnerabilities. Investors should scrutinize the company's supplier management and quality control processes.
5. Review the company's long-term strategy for revenue generation: With no proceeds from the current resale, investors need to understand how iSpecimen plans to fund its operations and achieve profitability.

Key Dates

• 2025-09-08: S-1/A Filing — Registers shares for resale and discloses new blockchain treasury plan and Nasdaq noncompliance.
• 2025-06-04: Nasdaq Noncompliance Letter — Indicates potential delisting risk if compliance is not regained.
• 2025-08-20: Original S-1 Filing — Initial registration statement that is now being amended.
• 2025-08-29: SEC Comment Letter — Prompted the S-1/A amendments, suggesting SEC review and potential disclosure deficiencies.
• 2024-09-13: Reverse Stock Split — A 1-for-20 reverse stock split, often undertaken to meet exchange listing requirements or improve stock price perception.
• 2025-09-05: Last Reported Sale Price — Provides a recent valuation benchmark for the company's common stock at $0.8536.

Glossary

S-1/A

An amended registration statement filed with the U.S. Securities and Exchange Commission (SEC) to update or correct information in an initial S-1 filing. (This filing is an amendment to iSpecimen's registration statement, indicating updates to its disclosures.)

Selling Stockholders

Existing shareholders who are offering to sell their shares of the company's stock. (The primary purpose of this S-1/A is to allow these stockholders to resell shares acquired in a private placement.)

Warrant Shares

Shares of common stock that can be purchased by the holder of a warrant at a specified price. (A significant portion of the shares being registered are issuable upon exercise of warrants from a recent private placement.)

Corporate Treasury Plan

A company's strategy for managing its cash reserves and investments, including how it holds and utilizes its treasury assets. (iSpecimen is disclosing a new plan involving the Solana blockchain ecosystem for its corporate treasury.)

Emerging Growth Company

A designation under the JOBS Act for companies with less than $1.235 billion in annual gross revenue, allowing for scaled disclosure requirements. (iSpecimen qualifies as an EGC, impacting the level of detail required in its SEC filings.)

Nasdaq Listing Rule 5550(b)(1)

A rule that typically requires listed companies to meet certain financial standards, such as minimum bid price or market capitalization. (iSpecimen's noncompliance with this rule poses a risk of delisting from the Nasdaq stock exchange.)

Year-Over-Year Comparison

This S-1/A filing represents a significant update from previous disclosures, primarily due to the registration of shares from a recent private placement and the introduction of a novel corporate treasury plan utilizing the Solana blockchain. While specific financial metrics for comparison are not detailed in the provided context, the filing addresses a critical Nasdaq noncompliance issue that was not present or as prominent previously. The company's reliance on private capital raises and the associated resale of shares by stockholders are key points of focus in this amendment, suggesting a potential shift in financing strategy or market conditions since the original S-1 filing.

Key Financial Figures

• $0.0001 — 9,828 shares of common stock, par value $0.0001 per share, of iSpecimen, Inc., held by
• $0 — t a nominal exercise price per share of $0.0001, without expiration, all of which
• $0.8536 — ted sale price for our common stock was $0.8536 per share. We are an "emerging growth

Filing Documents

• ea0256101-s1a2_ispecimen.htm (S-1/A) — 2126KB
• ea025610101ex23-1_ispecimen.htm (EX-23.1) — 2KB
• ea025610101ex23-2_ispecimen.htm (EX-23.2) — 3KB
• image_001.jpg (GRAPHIC) — 13KB
• ex23-2_001.jpg (GRAPHIC) — 19KB
• 0001213900-25-085541.txt ( ) — 9295KB
• ispc-20250630.xsd (EX-101.SCH) — 71KB
• ispc-20250630_cal.xml (EX-101.CAL) — 90KB
• ispc-20250630_def.xml (EX-101.DEF) — 411KB
• ispc-20250630_lab.xml (EX-101.LAB) — 670KB
• ispc-20250630_pre.xml (EX-101.PRE) — 440KB
• ea0256101-s1a2_ispecimen_htm.xml (XML) — 1160KB

Use of Proceeds

Use of Proceeds 34 Dividend Policy 34

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 34

Business

Business 48 Management 62

Executive Compensation

Executive Compensation 67 Certain Relationships and Related Party Transactions 74 Principal Stockholders 75

Description of Securities

Description of Securities 76 August 2025 Private Placement 78 Selling Stockholders 79 Plan of Distribution 80 Legal Matters 81 Experts 81 Where You Can Find More Information 81 Index to Financial Statements F-1 i ABOUT THIS PROSPECTUS This prospectus describes the general manner in which the Selling Stockholders may offer from time to time the Shares and Warrant Shares. You should rely only on the information contained in this prospectus and the related exhibits, any prospectus supplement or amendment thereto and the documents incorporated by reference, or to which we have referred you, before making your investment decision. Neither we nor the Selling Stockholders have authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus, any prospectus supplement or amendments thereto do not constitute an offer to sell, or a solicitation of an offer to purchase, the common stock offered by this prospectus, any prospectus supplement or amendments thereto in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. You should not assume that the information contained in this prospectus, any prospectus supplement or amendments thereto, as well as information we have previously filed with the U.S. Securities and Exchange Commission (the "SEC"), is accurate as of any date other than the date on the front cover of the applicable document. If necessary, the specific manner in which the shares of common stock may be offered and sold will be described in a supplement to this prospectus, which supplement may also add, update or change any of the information contained in this prospectus. To the extent there is a conflict between the information contained in this prospectus and any prospectus supplement, you should rely on the information in such prospectus

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This prospectus and the documents incorporated by reference herein contains various forward-looking statements various forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities and Exchange Act of 1934, as amended (the "Exchange Act") that reflect our current expectations and views of future events. The forward-looking statements are contained principally in the sections included or incorporated by reference herein entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Readers are cautioned that known and unknown risks, uncertainties and other factors, including those over which we may have no control and others listed in the "Risk Factors" section of this prospectus, may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You can identify some of these forward-looking "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include statements relating to: our ability to enter into contracts with healthcare providers to gain access to specimens, subjects, and data on favorable terms; our ability to obtain new customers and keep existing customers; development of our technology to adequately keep pace to support expansion of our existing line of business or our entry into new lines of businesses; market adoption rate of our marketplace technology; our ability to continue to expand outside of the United

View Full Filing

View this S-1/A filing on SEC EDGAR